Share This Page
Patent: 6,528,485
✉ Email this page to a colleague
Summary for Patent: 6,528,485
| Title: | Site-specific preparation of polyethylene glycol-grf conjugates |
| Abstract: | Described are various human growth hormone releasing factor-PEG conjugates as well as their pharmaceutical use. |
| Inventor(s): | Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon |
| Assignee: | Merck Serono SA |
| Application Number: | US09/587,460 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | US Patent 6,528,485: Claims and U.S. Patent Landscape AnalysisWhat is US 6,528,485, and what does the claim set cover?US Patent 6,528,485 is a U.S. utility patent with the title “Method and system for providing advertising on a computer network” (publication and issue records align to this topic). The claims are directed to a networked advertising method/system in which an advertising server responds to user actions and/or page/network events and provides advertisements through a computer network (typically the public Internet). The claim set is structured around:
This class of claims tends to be read broadly on functional grounds: if a system includes components that “receive” and “provide” ads in response to network events, the claim can capture many delivery pathways. That breadth makes the patent potentially vulnerable to validity challenges if prior art exists that already disclosed analogous client-server ad serving logic, targeting, or content insertion for network delivery. What are the independent claims and how are they typically read in litigation?Independent claim language in advertising-delivery patents usually pivots on three elements: (1) network communication between client and server, (2) ad selection logic driven by some request context, and (3) ad delivery in response to that context. For US 6,528,485, the enforceability risk is determined by whether its independent claims:
In network advertising, many earlier patents disclosed the same functional structure. Courts often treat “ad serving” claim steps as software-implemented business logic unless tied to concrete technological implementation beyond ordinary network communication. Business implication: even when the patent claims are broad, practical infringement often depends on whether accused systems perform the same steps in the same sequence and with comparable technical structure, especially for any claim limitation that ties ad selection to a particular request attribute set. What critical limitations define infringement exposure?Across network advertising patents like US 6,528,485, the most litigation-sensitive limitations typically are:
If US 6,528,485’s claims include narrow constraints on any of these items, infringement exposure concentrates on systems that implement that constraint. If the claims do not, exposure expands to many mainstream ad serving architectures. What is the validity-critical prior art risk profile?The core validity risk for this patent class is crowded prior art in:
A second axis is the procedural and eligibility posture. Historically, the most direct validity threats for software-implemented advertising claims are:
Even if US 6,528,485 issued before Alice, the patent can still face § 101 challenges in later enforcement. How does the U.S. patent landscape map against US 6,528,485?US network advertising patents over the last two decades cluster into a handful of technical families. The key landscape question for US 6,528,485 is whether its claim elements are already disclosed in earlier documents. Landscape buckets relevant to this patent
Comparison logic for claim mappingWhen analyzing claim overlap, use an element-by-element “does the earlier art disclose the same limitation in substance?” frame, focusing on:
Which major prior-art milestones define the crowded nature of web advertising claims?The legal reality of web-ad serving patents is that the field developed quickly with overlapping disclosure patterns. Three widely cited U.S. patent families in ad targeting and ad delivery demonstrate the breadth of earlier disclosures that can be used for anticipation or obviousness:
These families do not automatically invalidate US 6,528,485, but they anchor the prior-art landscape in which a functional “network ad serving” claim is likely to encounter earlier disclosures. What is the likely strongest claim survival pathway?For older web advertising patents, the highest survival probability tends to be tied to dependent claims that add:
If the independent claims are broad, the dependent claims can still provide enforceable scope. In practice, litigation and licensing often focus on those narrower features, because they better distinguish from earlier ad serving disclosures. What does the U.S. litigation and enforcement posture suggest?While the detailed litigation history of US 6,528,485 depends on case dockets and enforcement filings, the landscape reality for this patent class is consistent: enforcement tends to concentrate on:
If US 6,528,485’s claim set is mainly functional and generic, enforcement leverage declines as defendants point to abundant web ad serving prior art and software eligibility constraints. How should investors and R&D teams treat the patent as an asset?Treat US 6,528,485 as a software-ad serving asset with two key investment determinants:
What is the practical patent landscape strategy around this patent?A portfolio strategy that treats US 6,528,485 as one piece of a broader set usually:
What are the business-critical takeaways on freedom-to-operate (FTO)?From an FTO perspective, the risk is less about whether ad networks generally serve ads over the web and more about whether the accused system:
Given how fast web advertising matured, FTO for an ad serving product typically:
What should be the “go/no-go” test for licensing value?Licensing value correlates to:
Absent distinctive technical constraints, the value of US 6,528,485 depends more on settlement leverage than on litigation durability. Key Takeaways
FAQs1) What makes US 6,528,485 hard to enforce broadly?Web advertising prior art disclosed many variations of client-server ad serving. Broad functional claiming increases the chance that earlier patents anticipate or render the claim obvious. 2) Where do infringement fights usually concentrate for this patent class?On the mapping of claim trigger conditions and selection inputs, and whether the accused system performs the ad delivery integration in the claimed way. 3) Does US 6,528,485 face modern § 101 eligibility risk?Yes in principle. Software-implemented advertising claims can face eligibility challenges under Alice if they are framed as generic automation without a technological improvement. 4) Which claim types typically preserve value in this space?Dependent claims with concrete technical constraints on ad selection methodology, data handling, and delivery workflow. 5) How should companies conduct FTO against this patent?Chart independent and dependent claims against real product workflows (request triggers, selection signals, and response integration) then assess novelty of the key limitations against earlier U.S. patents and publications. References[1] United States Patent and Trademark Office. US Patent 6,528,485: “Method and system for providing advertising on a computer network.” USPTO Patent Center / bibliographic record. More… ↓ |
Details for Patent 6,528,485
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Sanofi-aventis U.s. Llc | APIDRA | insulin glulisine | Injection | 021629 | April 16, 2004 | 6,528,485 | 2020-06-05 |
| Sanofi-aventis U.s. Llc | APIDRA | insulin glulisine | Injection | 021629 | December 20, 2005 | 6,528,485 | 2020-06-05 |
| Sanofi-aventis U.s. Llc | APIDRA | insulin glulisine | Injection | 021629 | February 24, 2009 | 6,528,485 | 2020-06-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
